Litigation preparedness
2023 Annual Litigation Trends Survey
Global | Publication | January 18, 2023
Norton Rose Fulbright’s 2023 Annual Litigation Trends Survey finds that more legal spending is moving in-house, and organizations feel largely prepared to address litigation in the year ahead.
Respondents attributed that confidence to several factors including their organization’s in-house litigation experience and confidence in external counsel. Also cited were internal risk management practices and in-house tools and capabilities such as eDiscovery platforms and data protection solutions.
Some in-house legal operations have room to grow when it comes to technology. For example, nearly one-quarter (24%) weren’t considering the use of artificial intelligence or predictive analytics to spot risk. Compliance tools like Norton Rose Fulbright’s NT Analyzer can help detect privacy and security risks associated with mobile apps, websites and the Internet of Things (IoT) amid growing data privacy concerns and revamped privacy laws at the state level. California and Virginia have already enacted comprehensive privacy laws, and Colorado, Connecticut and Utah are expected to follow suit later this year.
Just sixteen percent of respondents said they weren’t considering the use of litigation software, the same number of respondents that said the use of legal technology was a low priority.
Download the 2023 Annual Litigation Trends Survey for more details.
This issue
Recent publications
Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
The GCR Guide to Life Sciences – Merger control: Procedural issues
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .